Agenus
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3 Forbes Rd, Lexington, Massachusetts, 0...Phone Number
(781) 674-4400Website
www.agenusbio.comRevenue
$123.9 MillionStock Symbol
AGENIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Agenus
Agenus researches, develops, and manufactures immuno-oncology products such as, checkpoint antibodies, cell therapies, vaccines and adjuvants. The company's proprietary discovery engine Retrocyte Display is used to generate fully human therapeutic antibody drug candidates. The headquarters is located in Lexington, Massachusetts.Explore more
Agenus Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Agenus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Agenus launches new products
Agenus, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Agenus
Funding: Get notified immidiatlly once Agenus has new funding data
Check if Agenus has recently received funding, and reach out quickly before it becomes old news!
Click to see if Agenus had a recent Job posting/layoffs
Earning: See what the market has to say on Agenus recently announced quarterly report
Check out if Agenus is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Agenus
Compare insights from companies similar to Agenus, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Agenus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Agenus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Agenus.
Agenus financials insights
Gather financial insights about Agenus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Share Placement
$10M
2013
Debt
$5M
2015
Debt
$21.1M
Debt
$100M
2017
Share Placement
$60M
2018
Debt
$230M
2020
Debt
$1M
Private Equity
$35M
Agenus Tech Stack
A closer look at the technologies used by Agenus
See more technologies
Most Recent Scoops
Project
Agenus has made a strategic decision to prepare simultaneous regulatory submissions to the FDA and EMA for accelerated approval and conditional marketing authorization of BOT+BAL, with submissions expected within a few quarters. The package will include validated data from mature clinical datasets and a safety dataset covering over 1,300 patients.
Clinical Operations, Regulations
Project
presented melanoma trial data at ASCO showing that BOT+BAL achieved a 22% confirmed overall response rate in 36 refractory patients, with a 29% response rate in the subgroup that had failed both CTLA-4 and PD-1 therapy, and survival plateaus between 40% and 60% at a minimum follow-up of 2.5 years.
Medical Research, Clinical Operations
Earnings
Agenus has reported pre-commercial product revenue of $3.2 million for Q4 2025 and $4.6 million for Q1 2026, representing income from BOT+BAL provided to hospitals and treating physicians under regulatory access programs.
Earnings, Doctors / Physicians, Pharmaceuticals, Finance
Project
Agenus has reported that BOT+BAL demonstrated a 42% two-year overall survival rate and a median overall survival of approximately 21 months in heavily pretreated MSS metastatic colorectal cancer patients without active liver metastases. This represents a significant clinical milestone in a setting where immunotherapy has historically shown no benefit.
Medical Research
Project
Medical Research
Agenus News & Media
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer July 13, 2026 8:30 AM EDTCompany...Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing
Agenus (NASDAQ:AGEN) said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk stage 2 and stage 3 microsatellite stable colon cancer. Founder, Chairman and Chief Executive OffAgenus Raises $85 Million in Private Placement, Warrants Could Add $255 Million More
Agenus announced a private placement expected to raise approximately $85 million in gross proceeds at a combined purchase price of $3.69 per unit, alongside Series A and Series B warrants that could generate up to an additional $255 million if fully exercised. Closing is expected on Jul 15, 2026. I…Agenus’ metastatic colorectal cancer combo achieves 33% three-year OS rate
Three-year data from the Phase Ib trial of BOT+BAL was unveiled at ESMO GI 2026.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Agenus
Sign Up For FreeTo access detailed company insights
Agenus researches, develops, and manufactures immuno-oncology products such as, checkpoint antibodies, cell therapies, vaccines and adjuvants. The company's proprietary discovery engine Retrocyte Display is used to generate fully human therapeutic antibody drug candidates. The headquarters is located in Lexington, Massachusetts.... Read More
